Biofrontera’s 10% Ameluz topical gel, used with the BF-RhodoLED lamp series, won FDA approval for superficial basal cell carcinoma in adults. The indication expands Ameluz’s addressable market, and Biofrontera plans to launch through its existing commercial organization from late fourth quarter 2026 through first quarter 2027.
Key Highlights
- Biofrontera plans to launch the new Ameluz indication from late fourth quarter 2026 through first quarter 2027.
- Superficial basal cell carcinoma represents approximately 15%-20% of U.S. basal cell carcinoma cases, or an estimated 540,000 to 720,000 cases annually.
- Ameluz PDT produced a 66% complete clinical and histological response rate versus 5% for placebo-PDT in the supporting trial.
Biofrontera Inc. (NASDAQ: BFRI) received FDA approval for its 10% Ameluz topical gel, used with the BF-RhodoLED lamp series to treat superficial basal cell carcinoma in adults. The approval makes Ameluz the first and only photodynamic therapy drug approved in the United States for a skin cancer.
Launch Plan Uses Existing PDT Footprint
The new indication uses the same Ameluz product and red-light device as Biofrontera’s actinic keratosis treatment. Existing customers can therefore adopt the option with their current equipment, while new dermatology practices may purchase a RhodoLED lamp and begin using Ameluz PDT. Biofrontera plans an official launch from late fourth quarter 2026 through first quarter 2027. The company plans to use its existing commercial organization and installed lamp base for the rollout.
Ameluz Market Opportunity and Trial Evidence
Approximately 3.6 million basal cell carcinoma cases are diagnosed annually in the United States. The superficial subtype represents approximately 15%-20% of basal cell carcinoma cases, equal to an estimated 540,000 to 720,000 cases each year. Complete clinical and histological response reached 66% with Ameluz PDT, compared with 5% with placebo-PDT. Histological clearance was 76% versus 19%, while complete clinical clearance of all target lesions reached 83% versus 21%.
FAQs
Q: What did the FDA approve for Biofrontera?
A: The FDA approved Biofrontera’s supplemental application for Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, used with photodynamic therapy and the BF-RhodoLED lamp series. It is indicated for superficial basal cell carcinoma in adults.
Q: When will Biofrontera launch the new Ameluz indication?
A: Biofrontera plans an official launch of the superficial basal cell carcinoma indication from late fourth quarter 2026 through first quarter 2027. The company said the rollout will use its existing commercial organization and installed lamp base.
Q: What did the Ameluz clinical trial show?
A: In the supporting Phase 3 trial, complete clinical and histological response was 66% among subjects treated with Ameluz PDT, compared with 5% among those treated with placebo-PDT. The study included adults with histologically confirmed superficial basal cell carcinoma.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.